What do the new results change?

The trial results give researchers a concrete reason to keep investing in anti-tau approaches. After years in which amyloid dominated clinical pipelines — producing both landmark approvals and high-profile failures — the field now has evidence that targeting the other pathological pathway can also bear fruit.

This matters because Alzheimer's is unlikely to fall to a single mechanism. If amyloid drugs and tau drugs each slow the disease through different routes, combination therapy becomes a realistic long-term goal.

What should readers keep in mind?

The results are preliminary in the sense that all trial findings require replication, longer follow-up, and larger patient groups before they change standard care. Translating a promising trial readout into an approved, widely available treatment typically takes years.

Scientists also caution that "targeting tau" covers several distinct strategies — from antibodies that clear the protein to drugs that block its aggregation — and trial success for one approach does not automatically validate the others.

Still, the direction is clear. The field's center of gravity is broadening, and tau has moved from a supporting role in Alzheimer's biology to a leading target in the clinic.